CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) has received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that […]
Shares of CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) have earned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target […]
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) has received an average recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that […]
Operator: Good morning, and welcome to the CTI BioPharma Fourth Quarter and Year-End 2022 Financial Results and Corporate Update Conference Call. As a reminder, this conference call is being recorded.
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) CFO David Kirske sold 60,000 shares of the firm’s stock in a transaction dated Friday, June 17th. The stock was sold at an average price of $6.21, for a total transaction of $372,600.00. Following the completion of the transaction, the chief financial officer now directly owns 7,397 shares […]